In Brief: Copley
Executive Summary
Copley: VP-Scientific Affairs Jerome Skelly resigns. Skelly, who headed FDA's Division of Biopharmaceutics from 1983 to 1988, will continue to work for Copley as an outside R&D consultant. Copley is considering internal and external candidates for the VP position. The company is also considering whether further workforce reductions are necessary. Copley is scheduled for an initial appearance before Boston Federal Judge Joseph Tauro during the week of June 9 to review a $10.7 mil. fraud settlement reached with the U.S. Attorney's office. The generic drug maker is a subsidiary of Hoechst AG ("The Pink Sheet" June 2, T&G-10)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth